
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group Inc. has increased the probability of approval for its RP1 + Opdivo combination therapy in anti-PD1 failed melanoma patients to 85%, reflecting strong confidence in the clinical efficacy of its product pipeline. The company reported a favorable safety profile for RP1 + Opdivo, with only 12.8% of patients experiencing grade 3 or higher treatment-related adverse events, which may further support regulatory approval. These positive developments, alongside promising trial results, enhance the company's outlook as it continues to focus on innovative oncolytic immunotherapies for cancer treatment.
Bears say
Replimune Group faces significant risks that jeopardize its future prospects, primarily stemming from its inability to generate compelling efficacy and safety data for its lead product, RP1, in upcoming clinical trials. Concerns raised by the FDA regarding the adequacy of the IGNYTE trial and the heterogeneity of the patient population hinder the credibility of the clinical evidence supporting RP1, further complicating potential regulatory approvals. Additionally, the company may encounter medium- to long-term dilution risk, which could negatively impact shareholder value as it strives to deliver on its early-stage pipeline of oncolytic virus candidates.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares